patrik brundin - are synucleinopathies prion diseases?
TRANSCRIPT
![Page 1: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/1.jpg)
ARE SYNUCLEINOPATHIES PRION DISEASES?
Patrik Brundin, MD, PhD Center for Neurodegenerative Science
Van Andel Research Institute Grand Rapids, Michigan, USA
Alzforum WebinarApril 8, 2016
![Page 2: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/2.jpg)
Evidence from:
Post-mortem studies Cell culture experiments Animal models
Why should synucleinopathies be called prion diseases?
![Page 3: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/3.jpg)
Lewy bodies can develop in healthy immature neurons grafted to PD (but not in HD) patients
Why should synucleinopathies be called prion diseases?
Phospho-S129-α-synuclein
Ubiquitin Thioflavin S
Li et al. 2008 and 2010.
![Page 4: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/4.jpg)
Cell culture models demonstrate cell-to-cell transfer and seeding
α-synuclein Release uptake seeding transport
Vekrellis et al. 2011
![Page 5: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/5.jpg)
Why should synucleinopathies be called prion diseases?
Injections can trigger progressive α-synucleinopathy that follows anatomically distinct neural pathways and induces functional deficits
• mouse brain extracts containing α-synuclein aggregates • recombinant α-synuclein fibrils • autopsy-derived brain extracts (PD, DLB, MSA) • peripheral inoculation is effective
![Page 6: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/6.jpg)
Why should synucleinopathies be called prion diseases?
Injections can trigger progressive α-synucleinopathy that follows anatomically distinct neural pathways and induces functional deficits
• mouse brain extracts containing α-synuclein aggregates • recombinant α-synuclein fibrils • autopsy-derived brain extracts (PD, DLB, MSA) • peripheral inoculation is effective
![Page 7: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/7.jpg)
PNAS 2013
Mouse brain
Recombinant fibrils
DLB
MSA
PD
![Page 8: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/8.jpg)
Why should synucleinopathies be called prion diseases?
Injections can trigger progressive α-synucleinopathy that follows anatomically distinct neural pathways and induces functional deficits
• mouse brain extracts containing α-synuclein aggregates • recombinant α-synuclein fibrils • autopsy-derived brain extracts (PD, DLB, MSA) • peripheral inoculation is effective
![Page 9: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/9.jpg)
![Page 10: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/10.jpg)
Why should synucleinopathies be called prion diseases?
Injections can trigger progressive α-synucleinopathy that follows anatomically distinct neural pathways and induces functional deficits
• mouse brain extracts containing α-synuclein aggregates • recombinant α-synuclein fibrils • autopsy-derived brain extracts (PD, DLB, MSA) • peripheral inoculation is effective
![Page 11: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/11.jpg)
Normal mice
α-synuclein fibrils into olfactory bulb
Spreading along anatomical pathways
Rey et al. submitted
![Page 12: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/12.jpg)
Spreading of Pser129 α-syn pathology
Rey et al. submitted
![Page 13: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/13.jpg)
Rey et al. submitted
1 mo after α-synuclein fibril injection
Thioflavin S staining (green) Nuclear stain (blue)
Thioflavin S-positive aggregates and behavioural deficits
Odor retention test
Delay
![Page 14: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/14.jpg)
The fundamental molecular mechanism that unifies the templating capacity of prion-like proteins is the nucleated transformation of protein conformation.
In this spirit, we suggest that “prion” should be defined broadly as a “proteinaceous nucleating particle” (rather than a “proteinaceous infectious particle”).
Adapted from Walker and Jucker, Annu Rev Neurosci 2015
Expanding the prion concept
![Page 15: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/15.jpg)
This expanded and refined definition could help to obviate unnecessary confusion and concern about the communicability of noninfectious proteopathies and speed acceptance of this important paradigm within the biomedical community.
….allows the prudent inclusion of noninfectious proteopathies under the umbrella of the prion concept.
Expanding the prion concept
Adapted from Walker and Jucker, Annu Rev Neurosci 2015
![Page 16: Patrik Brundin - Are Synucleinopathies Prion Diseases?](https://reader034.vdocuments.site/reader034/viewer/2022042619/587081b11a28ab57368b6851/html5/thumbnails/16.jpg)
Concluding remarks - α-synuclein
• Release, uptake, seeding, transport
• Transfer between brain regions is gradual and anatomically faithful
• Peripheral inoculation is effective
• Emerging evidence for α-synuclein strains
• Propagated pathology causes functional deficits